Processa expands NGC-Cap into breast cancer; FDA agrees existing data supports Phase 2 trial

Processa Pharmaceuticals, Inc.

FDA agreed existing data can directly support Phase 2 breast cancer trial design.
Plan to initiate Phase 2 study in advanced/metastatic breast cancer in Q3 2024.
Breast cancer represents larger market than colorectal; potential for >250,000 patients/year.
Company identified breast cancer KOLs for scientific advisory board.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.